Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study

Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study

Abstract This phase 1, multi‐center, nonrandomized, open‐label, dose‐escalation study consisted of Part A wherein merestinib 80 or 120 mg (40‐mg tablets) was administered orally QD during a 28‐day cycle to patients diagnosed with solid tumors and Part B wherein merestinib 80 mg (40‐mg tablets) was a...

Full description

Bibliographic Details
Main Authors: Toshihiko Doi, Noboru Yamamoto, Yoichi Naito, Yasutoshi Kuboki, Takafumi Koyama, Yongzhe Piao, Naoto Tsujimoto, Hiroya Asou, Koichi Inoue, Shunsuke Kondo
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Cancer Medicine
Subjects:
biliary tract neoplasms
carcinoma
metastasis
phosphotransferases
toxicity
Online Access:https://doi.org/10.1002/cam4.4110

Internet

https://doi.org/10.1002/cam4.4110

Similar Items